BioCryst Pharmaceuticals is trading 4.15% down at $10.15, with no clear company-specific announcement or analyst action identified for August 13, 2026.

  • The S&P 500, Nasdaq Composite, and Dow Jones were higher, so broader risk-on sentiment does not explain the decline.
  • Recent coverage highlights strong second-quarter results and raised revenue guidance; RBC’s price-target cut occurred August 6.
  • Trading activity and volume details were unavailable, leaving the immediate catalyst unclear.